54-97-7

Basic information

• Product Name: 2-Phenylcyclopropane-1-amine
• Synonyms: 1-Amino-2-phenylcyclopropane;2-Phenylcyclopropane-1-amine;2-Phenylcyclopropylamine;2-Phenylcyclopropan-1-amine;Cyclopropanamine, 2-phenyl-
• CAS NO: 54-97-7
• Molecular Formula: C₉H₁₁N
• Molecular Weight: 133.1903
• Mol File: 54-97-7.mol
• Article Data: 27

Chemical Properties

• Boiling Point: 218.3 °C at 760 mmHg
• Flash Point: 90.8 °C
• Appearance: /
• Density: 1.065 g/cm³
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 2-Phenylcyclopropane-1-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Phenylcyclopropane-1-amine(54-97-7)
• EPA Substance Registry System: 2-Phenylcyclopropane-1-amine(54-97-7)

Safety Data

• Hazardous Substances Data: 54-97-7(Hazardous Substances Data)

Usage

Description

2-Phenylcyclopropane-1-amine is an organic compound with the molecular formula C9H11N. It is a derivative of cyclopropane with a phenyl group attached to the second carbon and an amine group attached to the first carbon. 2-Phenylcyclopropane-1-amine is known for its potential applications in various industries due to its unique chemical structure and properties.

Uses

Used in Pharmaceutical Industry:
2-Phenylcyclopropane-1-amine is used as an intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows it to be a versatile building block for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
2-Phenylcyclopropane-1-amine is used as a reagent for the preparation of oxadiazole derivatives, which are known for their fungicidal properties. These derivatives can be used in the development of new fungicides to protect crops from fungal infections, thereby increasing agricultural productivity and crop yield.

Upstream product

• 6630-33-7 ortho-bromobenzaldehyde 
• 13492-01-8 2-phenylcyclopropanamine hemisulfate 
• 155-09-9 trans-2-phenylcyclopropylamine 
• 185256-47-7 (-)-(1R,2S)-trans (2-phenyl-cyclopropyl)carbaminic acid tert-butyl ester 
• 1521265-16-6 (1R,2S)-2-methoxy-N-(2-phenyl-cyclopropyl)-acetamide 
• 14561-40-1 (+/-)-cis-2-phenyl-cyclopropane-carboxylic acid-⁽¹⁾-hydrazide 
• 583-55-1 1-Bromo-2-iodobenzene 
• 220247-82-5 N,N-dibenzyl-N-(2-phenylcyclopropyl)-amine 
• 874341-82-9 [(1S,2R)-2-nitrocyclopropyl]benzene 
• 100-42-5 styrene 
• 5685-38-1 2-phenyl-cyclopropanecarboxylic acid 
• 928054-80-2 (-)-trans-2-phenylcyclopropanecarboxylic acid (2-hydroxy-1-phenylethyl)amide 
• 4192-77-2 ethyl cinnamate 
• 946-38-3 ethyl 2-phenylcyclopropylcarboxylate 

Downstream Products

• 97905-55-0 N⁶-[(1R,2S)-2-phenyl-1-cyclopropyl]adenosine 
• 1006-66-2 5-phenyl-4,5-dihydroisoxazole 
• 132350-68-6 (2-Nitro-cyclopropyl)-benzene 
• 65-85-0 benzoic acid 
• 50584-02-6 trans-2-Benzamido-1-phenyl-cyclopropan 
• 1521265-14-4 (2S,3S,4S)-4-fluoro-3-methoxy-2-((1R,2S)-2-phenyl-cyclopropylcarbamoyl)-pyrrolidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

CYCLOPROPYLAMINE COMPOUND AS LSD1 INHIBITOR AND USE THEREOF

Provided is a cyclopropylamine compound as lysine-specific demethylase 1 (LSD1) inhibitor, and a use thereof in preparation of drug for treating diseases associated with LSD1. The cyclopropylamine compound is a compound represented by formula (I), an isomer thereof, and a pharmaceutically acceptable salt thereof.

Synthetic method for arylcyclopropylamine compound

The invention relates to a synthetic method for an arylcyclopropylamine compound. The method comprises the following steps: with a cinnamaldehyde compound as a raw material, reacting the cinnamaldehyde compound with bis(pinacolato)diboron to obtain a boroalkylated product; and then subjecting the boroalkylated product and an aminated compound to a ring-closure reaction so as to obtain the arylcyclopropylamine compound. Compared with the prior art, the invention has the following advantages: the synthetic method of the invention is simple to operate and short in reaction time; reagents used inthe invention are cheap and easily available; the target arylcyclopropylamine compound can be prepared from most substrates at a high overall yield and is mainly in the form of transconfiguration; anda route of the method is obviously improved, more economical, safer and easy for industrial production.

Targeting Cancer with PCPA-Drug Conjugates: LSD1 Inhibition-Triggered Release of 4-Hydroxytamoxifen

Targeting cancer with small molecule prodrugs should help overcome problems associated with conventional cancer-targeting methods. Herein, we focused on lysine-specific demethylase 1 (LSD1) to trigger the controlled release of anticancer drugs in cancer cells, where LSD1 is highly expressed. Conjugates of the LSD1 inhibitor trans-2-phenylcyclopropylamine (PCPA) were used as novel prodrugs to selectively release anticancer drugs by LSD1 inhibition. As PCPA-drug conjugate (PDC) prototypes, we designed PCPA-tamoxifen conjugates 1 a and 1 b, which released 4-hydroxytamoxifen in the presence of LSD1 in vitro. Furthermore, 1 a and 1 b inhibited the growth of breast cancer cells by the simultaneous inhibition of LSD1 and the estrogen receptor without exhibiting cytotoxicity toward normal cells. These results demonstrate that PDCs provide a useful prodrug method that may facilitate the selective release of drugs in cancer cells.